288 related articles for article (PubMed ID: 10889864)
21. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
[TBL] [Abstract][Full Text] [Related]
22. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.
Gallardo M; Silva A; Rubio L; Alvarez C; Torrealba C; Salinas M; Tapia T; Faundez P; Palma L; Riccio ME; Paredes H; Rodriguez M; Cruz A; Rousseau C; King MC; Camus M; Alvarez M; Carvallo P
Breast Cancer Res Treat; 2006 Jan; 95(1):81-7. PubMed ID: 16261400
[TBL] [Abstract][Full Text] [Related]
23. Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Kotsopoulos J; Lubinski J; Lynch HT; Neuhausen SL; Ghadirian P; Isaacs C; Weber B; Kim-Sing C; Foulkes WD; Gershoni-Baruch R; Ainsworth P; Friedman E; Daly M; Garber JE; Karlan B; Olopade OI; Tung N; Saal HM; Eisen A; Osborne M; Olsson H; Gilchrist D; Sun P; Narod SA
Cancer Causes Control; 2005 Aug; 16(6):667-74. PubMed ID: 16049805
[TBL] [Abstract][Full Text] [Related]
24. Perspectives in the clinical management of BRCA mutations carriers.
Savarese A; Cognetti F
J Exp Clin Cancer Res; 2002 Sep; 21(3 Suppl):31-5. PubMed ID: 12585651
[TBL] [Abstract][Full Text] [Related]
25. Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort study.
Phillips KA; Jenkins MA; Lindeman GJ; McLachlan SA; McKinley JM; Weideman PC; Hopper JL; Friedlander ML;
Clin Genet; 2006 Sep; 70(3):198-206. PubMed ID: 16922722
[TBL] [Abstract][Full Text] [Related]
26. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
[TBL] [Abstract][Full Text] [Related]
27. [Clinical and molecular diagnosis of inherited breast-ovarian cancer].
Chompret A
J Gynecol Obstet Biol Reprod (Paris); 2003 Apr; 32(2):101-19. PubMed ID: 12717301
[TBL] [Abstract][Full Text] [Related]
28. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
Hamel N; Kotar K; Foulkes WD
BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
[TBL] [Abstract][Full Text] [Related]
29. Frequency of BRCA1 and BRCA2 mutations in a clinic-based series of breast and ovarian cancer families.
Vaziri SA; Krumroy LM; Rostai M; Casey G
Hum Mutat; 2001; 17(1):74. PubMed ID: 11139249
[TBL] [Abstract][Full Text] [Related]
30. BRCA1 and BRCA2 mutation carriers as potential candidates for chemoprevention trials.
Levy-Lahad E; Krieger M; Gottfeld O; Renbaum P; Klein G; Eisenberg S; Lahad A; Kaufman B; Catane R
J Cell Biochem Suppl; 2000; 34():13-8. PubMed ID: 10762009
[TBL] [Abstract][Full Text] [Related]
31. Hereditary breast cancer. Risk assessment of patients with a family history of breast cancer.
Warner E; Heisey RE; Goel V; Carroll JC; McCready DR
Can Fam Physician; 1999 Jan; 45():104-12. PubMed ID: 10889863
[TBL] [Abstract][Full Text] [Related]
32. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.
Burke W; Daly M; Garber J; Botkin J; Kahn MJ; Lynch P; McTiernan A; Offit K; Perlman J; Petersen G; Thomson E; Varricchio C
JAMA; 1997 Mar; 277(12):997-1003. PubMed ID: 9091675
[TBL] [Abstract][Full Text] [Related]
33. Hereditary Risk of Breast and Ovarian Carcinoma: The Role of the Oncologist.
Frank TS
Oncologist; 1998; 3(6):403-412. PubMed ID: 10388131
[TBL] [Abstract][Full Text] [Related]
34. Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature.
Calderon-Margalit R; Paltiel O
Int J Cancer; 2004 Nov; 112(3):357-64. PubMed ID: 15382059
[TBL] [Abstract][Full Text] [Related]
35. Hereditary breast cancer.
Hill AD; Doyle JM; McDermott EW; O'Higgins NJ
Br J Surg; 1997 Oct; 84(10):1334-9. PubMed ID: 9361585
[TBL] [Abstract][Full Text] [Related]
36. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.
Loman N; Johannsson O; Kristoffersson U; Olsson H; Borg A
J Natl Cancer Inst; 2001 Aug; 93(16):1215-23. PubMed ID: 11504767
[TBL] [Abstract][Full Text] [Related]
37. 'Cancer doesn't have an age': genetic testing and cancer risk management in BRCA1/2 mutation-positive women aged 18-24.
Werner-Lin A; Hoskins LM; Doyle MH; Greene MH
Health (London); 2012 Nov; 16(6):636-54. PubMed ID: 22547552
[TBL] [Abstract][Full Text] [Related]
38. Ionizing radiation or mitomycin-induced micronuclei in lymphocytes of BRCA1 or BRCA2 mutation carriers.
Gutiérrez-Enríquez S; Ramón Y Cajal T; Alonso C; Corral A; Carrasco P; Cornet M; Sanz J; Ribas M; Baiget M; Diez O
Breast Cancer Res Treat; 2011 Jun; 127(3):611-22. PubMed ID: 20625817
[TBL] [Abstract][Full Text] [Related]
39. Breast cancer and gene testing: risk, rationale, and responsibilities of primary care providers.
Wilcox-Honnold PM
Lippincotts Prim Care Pract; 1998; 2(3):271-83. PubMed ID: 9644442
[TBL] [Abstract][Full Text] [Related]
40. The psychological impact of breast and ovarian cancer preventive options in BRCA1 and BRCA2 mutation carriers.
Borreani C; Manoukian S; Bianchi E; Brunelli C; Peissel B; Caruso A; Morasso G; Pierotti MA
Clin Genet; 2014 Jan; 85(1):7-15. PubMed ID: 24117034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]